Nature of Operations (Details) $ / shares in Units, $ in Thousands		1 Months Ended		9 Months Ended
	Feb. 25, 2021 USD ($) $ / shares	Sep. 30, 2022 USD ($) trial $ / shares shares	Aug. 31, 2022 USD ($) shares	Sep. 30, 2022 USD ($) trial $ / shares	Dec. 31, 2021 USD ($) $ / shares
Collaborative Arrangement and Arrangement Other than Collaborative
Number of clinical trials (trials) | trial		2		2
Accumulated deficit		$ (495,752)		$ (495,752)	$ (292,513)
Working capital		$ 607,800		$ 607,800	$ 352,900
Common stock, par value (usd per share) | $ / shares		$ 0.0001		$ 0.0001	$ 0.0001
Cash, cash equivalents and marketable securities		$ 651,900		$ 651,900	$ 432,700
At-The-Market Program | Cowen
Collaborative Arrangement and Arrangement Other than Collaborative
Common stock, par value (usd per share) | $ / shares	$ 0.0001
Sale of stock, consideration received on transaction	$ 200,000		$ 67,800
Sale of stock (in shares) | shares			2,247,500
Sale of stock, consideration received on transaction, gross proceeds			$ 69,700
Sale of stock, commission			$ 1,900
Sale of stock, shares remaining in offering, value				$ 130,300
Private Placement
Collaborative Arrangement and Arrangement Other than Collaborative
Sale of stock, consideration received on transaction		$ 216,800
Sale of stock (in shares) | shares		8,650,520
Sale of stock, consideration received on transaction, gross proceeds		$ 225,000
Sale of stock, price per share (usd per share) | $ / shares		$ 26.01		$ 26.01
Private Placement | GSK
Collaborative Arrangement and Arrangement Other than Collaborative
Sale of stock (in shares) | shares		2,050,819
Sale of stock, consideration received on transaction, gross proceeds		$ 75,000
Sale of stock, price per share (usd per share) | $ / shares		$ 36.57		$ 36.57
Premium rate paid on weighted average share price (percent)		25.00%
Premium term (days)		30 days